A few 2025 trials pointed in the same direction: toward treatments built to modify disease biology and better ways to measure ...

Friday, January 2, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, ...

XING Mobility will exhibit at CES 2026 in Las Vegas at the Las Vegas Convention Center, West Hall, Level 1, Booth #7059, ...

Bristol-Myers Squibb has become the latest drugmaker in the US to file a legal challenge to a block on a drug rebate model opposed by a Health and Human Services (HHS) department. Specifically, BMS is ...

Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...

COBENFY™ (xanomeline and trospium chloride) is a prescription medicine used to treat schizophrenia in adults. It is not known ...

Savings for Part D and Advantage enrollees depend largely on which plan they’re enrolled in, as not all plans are the same.

Negotiated lower Medicare costs for 10 popular prescription drugs went into effect Thursday. How much those savings will be ...

The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. | The emergence of ...

From prescriptions to hospitals to Medicaid, President Donald Trump's healthcare vision, with eligibility changes, will come ...

Could the pharmaceutical giant turn things around next year? Let's find out whether Bristol Myers Squibb is a buy, sell, or ...